Main APIs Home > PRODUCTS > Main APIs
Details


Tirofiban Hydrochloride

Synonyms: N-(Butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-L-tyrosine Hydrochloride Monohydrate; MK-0383; Tirofiban hydrochloride monohydrate
CAS No.: 150915-40-5
Purity: 98%~102%
Molecular Formula: C22H39ClN2O6S
Therapeutic Category: Cardiovascular
Quality Standard: In-House(injectable)
Documentations: GMP/DMF
Brand: Wanlong
Capacity: Commercially available


Description:
Appearance: White or almost white powder
Packaging: 25g~1kg per to request.
Storage: Store in sealed containers and keep away from light
Shelf Life: 24 months
Availability: In stock


Application:
Tirofiban hydrochloride is A Nonpeptide Glycoprotein IIb/IIIa Receptor Antagonist.
Tirofiban HCL is a reversible antagonist of fibrinogen binding to the platelet glycoprotein (GP) IIb/IIIa receptor, the major platelet surface receptor. GP IIb/IIIa plays a major role in the regulation of platelet adhesion and aggregation during hemostasis, and the GP IIb/IIIa receptor has been identified as the pivotal mediator of platelet aggregation. Therefore, tirofiban hydrochloride specifically inhibits fibrinogen-dependent platelet aggregation and prolongs bleeding times.


Reference/Other information:
Tirofiban is an Anti-angina drug, it is successfully developed by the United States Merck company. Patent Number is EP 478363, and in 1998 it was sold in the United States, the trade name is Aggrastat,it is clinically used in treating acute coronary syndromes, including unstable angina or non-Q-wave myocardial infarction, and percutaneous transluminal coronary angioplasty (PTCA) or atherosclerotic plaque excision patients with in combination with heparin.

Xi’an Wanlong Pharmaceutical, as a GMP manufacturer of both APIs and FDFs supplies both Tirofiban HCL API and Tirofiban hydrochloride and Sodium Chloride injection (trade name XIN TUO).



How tirofiban is used to prevent blood clotting?

Tirofiban is administered via intravenous infusion and is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). Wanlong Pharmaceutical is a leading tirofiban manufacturer in China and our Tirofiban API has been exported to other countries.


Cost effective

Wanlong Pharmaceutical, as a tirofiban manufacturer in China has been manufacturing and using this API for more than a decade. We have GMP, EU WC and DMF available for this product and are able to assist our customers with their registration at their local authorities. Plus, customers’ feedback turned out that our product is not only of trust in quality but also cost effective.




Inquiry